0 |
This phase, also called human micro-dosing studies, includes the administration of single sub-therapeutic doses of the studied drug to a small number of healthy subjects (10 to 15), to gather preliminary data on pharmacokinetics (PK). |
1 |
This phase tests side effects, maximum tolerated dose and the dose-limiting toxicity, and drug formulation in a small number (20–100) of (often healthy) individuals. |
2 |
This phase assesses the preliminary clinical safety and efficacy of selected doses in a dozen to a hundred patients with specific diseases. |
3 |
This phase includes thousands of patients who have the disease or condition, to confirm clinical efficacy, effectiveness, and safety (confirmatory or pivotal studies). |
4 |
Post-authorization safety studies, real world studies, and registries. |